Impact of <i>Helicobacter pylori</i> infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors

Abstract

In this largest study of its kind, <i>H. pylori</i> infection was associated with inferior survival in ICI-treated patients with gastric cancer. This suggests <i>H. pylori</i> status may be a prognostic marker of immune responsiveness. Future studies are needed to elucidate immunoregulatory mechanisms and whether treatment of active infections would improve immunotherapy outcomes.